Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $8.50, but opened at $8.93. Ginkgo Bioworks shares last traded at $9.14, with a volume of 287,788 shares trading hands.
Ginkgo Bioworks Stock Down 3.8%
The firm has a market cap of $523.22 million, a PE ratio of -0.68 and a beta of 1.25. The company's 50 day moving average price is $7.61 and its two-hundred day moving average price is $9.08.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The firm had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. SBI Securities Co. Ltd. bought a new position in shares of Ginkgo Bioworks in the fourth quarter worth about $29,000. Barclays PLC grew its holdings in shares of Ginkgo Bioworks by 353.6% in the fourth quarter. Barclays PLC now owns 54,166 shares of the company's stock worth $531,000 after purchasing an additional 42,224 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Ginkgo Bioworks by 15.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company's stock worth $412,000 after purchasing an additional 5,746 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Ginkgo Bioworks by 65.1% in the fourth quarter. Renaissance Technologies LLC now owns 114,654 shares of the company's stock worth $1,126,000 after purchasing an additional 45,200 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Ginkgo Bioworks in the fourth quarter worth about $665,000. 78.63% of the stock is currently owned by institutional investors.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
